Board of Directors

John Hohneker, M.D., has served on the Board since December 2021. He currently serves on the Board of Directors of ArriVent BioPharma, Inc., Carisma Therapeutics, Inc., Trishula Therapeutics, Inc., and Sonata Therapeutics, Inc. Dr. Hohneker previously served on the Board of Directors of Aravive, Inc., Torque Therapeutics, Inc., Dimension Therapeutics, Inc., Cygnal Therapeutics, Inc., BioTheryX Inc., Evelo Biosciences, and Humanigen, Inc.

Previously, Dr. Hohneker served as President and CEO of Anokion SA. Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the company’s transition from a discovery-stage biotech to one with multiple programs in clinical trials. During his tenure at Novartis AG, as SVP and Global Head of Development, Immunology and Dermatology, Dr. Hohneker played a critical role in the development and commercialization of many notable products including Cosentyx^®, Ilaris^®, Gleevec^®, Zometa^®, Tasigna^®, and Afinitor^®. Prior to joining Novartis, he held leadership positions at Glaxo Wellcome and its legacy company, Burroughs Wellcome.

Dr. Hohneker received his bachelor’s degree in chemistry from Gettysburg College and his M.D. from Rutgers School of Biomedical and Health Sciences. He completed his internship and residency in internal medicine and his fellowship in medical oncology, all at the University of North Carolina at Chapel Hill.

Committee:

Compensation